Results 11 to 20 of about 315,361 (205)
Differential Targeting of Stem Cells and Differentiated Glioblastomas by NK Cells. [PDF]
We have recently shown that Natural Killer (NK) cells control survival and differentiation of Cancer Stem-like Cells (CSCs) through two distinct phenotypes of cytotoxic and anergic NK cells, respectively. In this report, brain CSCs and their serum and NK
Bui, Vickie T +6 more
core +1 more source
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez +3 more
doaj +1 more source
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM).
Chen Zhu +17 more
doaj +1 more source
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds [PDF]
Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit ...
Abhishek Saxena +3 more
core +1 more source
Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production [PDF]
Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), based on the recognition of IgG-opsonized targets by the low-affinity receptor for IgG FcγRIIIA/CD16, represents one of the main mechanisms by which therapeutic antibodies
Battella, Simone +9 more
core +2 more sources
Background Despite strong efforts to improve clinical outcome of ovarian cancer patients by conventional and targeted immuno-based therapies, the prognosis of advanced ovarian cancer is still poor.
Gottschalk Nina +4 more
doaj +1 more source
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs.
Simone C. Oostindie +16 more
doaj +1 more source
Antitumor activity of an anti-CD98 antibody. [PDF]
CD98 is expressed on several tissue types and specifically upregulated on fast-cycling cells undergoing clonal expansion. Various solid (e.g., nonsmall cell lung carcinoma) as well as hematological malignancies (e.g., acute myeloid leukemia) overexpress ...
Cairns, Belinda +11 more
core +1 more source
Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients [PDF]
Natural Killer (NK) cells are a key component of tumor immunosurveillance and thus play an important role in rituximab-dependent killing of lymphoma cells via an antibody-dependent cellular cytotoxicity (ADCC) mechanism.
Battella, Simone +13 more
core +1 more source
Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.
HIV-1 infected cells are eliminated in infected individuals by a variety of cellular mechanisms, the best characterized of which are cytotoxic T cell and NK cell-mediated killing.
Adjoa Smalls-Mantey +2 more
doaj +1 more source

